



25th April, 2013

Ref: HL:SVW:2013

The Deputy General Manager The Bombay Stock Exchange Ltd. Corporate Relationship Department Phiroze Jeejebhoy Towers Dalal Street, Fort, Mumbai - 400 001

COMPANY CODE No. 524735

Dear Sir,

Re: <u>Intimation under Clause 36 of the listing agreement</u>

Sub: Hikal's 2nd Pharmaceutical Manufacturing Site in Gujarat, India received US FDA Approval

We are pleased to inform you that our second manufacturing facility located at Panoli, Dist. Bharuch, Gujarat, manufacturing pharmaceutical ingredients, intermediates and regulated starting materials successfully completed a US FDA audit and received the approval.

Hikal has already received US FDA approval for its pharmaceutical intermediates and active pharma ingredients (API's) manufacturing site located in Jigani, Bengaluru in Karnataka state.

This additional site approval will further add to capacities, which is beneficial to our customers. It will mitigate the risk of supply by having two sites certified by the US FDA. The additional site certification is a true testimony to the high standards of quality, regulatory compliance and operating standards at Hikal.

Both the sites have multipurpose facilities and capabilities which support Hikal's global customers. The pharmaceutical division is supported by 2 R&D centres based in Bangalore and Pune, India where they provide early stage research services, new product development all the way to successful commercialization. The API manufacturing site at Bangalore has been inspected 3 times by the US FDA.

Thanking you,

Yours faithfully, for Hikal Ltd.,

Kuldeep Jain

Head – Accounts & Taxation

cc: The National Stock Exchange of India Ltd. Mumbai

Symbol: HIKAL